Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441251 | 0.89 | ALK (0.58) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL2439011 | 0.89 | ALK (0.58) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL18357343 | 0.87 | ALK (0.44) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL12336334 | 0.76 | ALK (0.72) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL13711995 | 0.74 | PDGFRB (0.60) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL5642751 | 0.74 | PDGFRB (0.60) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL13711996 | 0.73 | KDR (0.52) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL5642503 | 0.73 | KDR (0.52) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL12335804 | 0.73 | ALK (0.53) | PDGFRBFGFR1ALKRETFLT3 | |
| SCHEMBL5511277 | 0.72 | KDR (0.49) | PDGFRBFGFR1ALKRETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-9162981-B2 | Compositions and methods for treatment of neurodegenerative disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2011119777-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | PDGFRB 3455/4885FGFR1 4629/4885ALK 4816/4885 |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | CLN6, PSEN2, CHAT | PDGFRB 3455/4885FGFR1 4629/4885ALK 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.